UCLA Health Jonsson Comprehensive Cancer Center’s Post

The 5-year survival rate for pancreatic cancer has increased to 13% according to the American Cancer Society (ACS) published the 2024 Cancer Facts & Figures Report. The report shares the latest information on pancreatic cancer and a notable rise in survivorship. This new data demonstrates a shift in pancreatic cancer outcomes and reflects worldwide efforts to change the trajectory of this disease. We know there is still much work to be done but we are headed in the right direction. Together, we will continue to make strides toward a cure. https://lnkd.in/g56dh82K

The fight against cancer demands innovation and collaboration. In 2021, we joined forces with UCLA to tackle the complexities of Ewing sarcoma and explore more precise immunotherapy options. This journey led to the groundbreaking Universal Cancer Vaccine Platform (UCV), designed to target cancer cells with laser focus while minimizing harm to healthy tissue. Our commitment to progress didn't stop there. In 2023, a serendipitous discovery revealed the potential to significantly reduce the cost of CAR-T cell therapy – a powerful but expensive treatment. This birthed the Universal CAR-T Cell Platform, aiming to make this life-saving therapy more accessible. Today, we stand at the forefront of cancer treatment with three promising projects: Ewing sarcoma research, the targeted UCV platform, and the affordable CAR-T platform. This multi-pronged approach has the potential to redefine the way we fight cancer. We remain dedicated to collaborating with UCLA to translate these innovations into tangible benefits for patients, empowering their bodies' natural defenses and improving overall outcomes. Visit us at www.cancervax.com to learn more

Breast cancer is the most common cancer in women. The two aggressive types, known as triple-negative breast cancer and HER2-enriched breast cancer, are associated with the poorest outcomes. They tend to develop resistance to existing treatments. In 2020, scientists at the Harry Perkins Institute of Medical Research in Perth, Australia, and the University of Western Australia, found that melittin and honeybee venom can kill these cancer cell membranes by 100% within 60 minutes, with negligible effects on normal cells. Melittin can kill cancerous cells in under 1 hour by punching holes in their outer membrane. However, within 20 minutes of administration, it also disrupts the passing of chemical messages that the cells need to grow and divide. The scientists discovered that melittin does this by preventing the activation of receptors for growth factors in the cells’ membrane. One of the reasons that HER2-enriched cancer cells and some triple-negative breast cancers grow uncontrollably is that they have large numbers of these receptors. By preventing these growth signals from getting through, melittin halts the cells’ proliferation. pic courtesy: Infomance Information courtesy: Medical News Today

The 5-year survival rate for #pancreaticcancer has increased to 13%, according to the American Cancer Society’s Cancer Facts & Figures 2024, released today! This statistic has increased three years in a row- a promising trend that points to continued progress for pancreatic cancer patients. There is more hope than ever before, but there is still more work to be done. PanCAN remains committed to our long-standing research priorities: To find an early detection strategy and accelerate treatments for patients with pancreatic cancer. Learn more at http://pcan.at/a25jq7

The 5-year survival rate for #pancreaticcancer has increased to 13%, according to the American Cancer Society’s Cancer Facts & Figures 2024, released today! This statistic has increased three years in a row- a promising trend that points to continued progress for pancreatic cancer patients. There is more hope than ever before, but there is still more work to be done. PanCAN remains committed to our long-standing research priorities: To find an early detection strategy and accelerate treatments for patients with pancreatic cancer. Learn more at http://pcan.at/a25jq7

A clinical trial led by researchers from UCL and UCLH has found cervical cancer patients are significantly more likely to be alive and cancer-free after five years when given a short course of chemotherapy prior to chemoradiation. The INTERLACE phase III trial, funded by Cancer Research UK (CRUK) and Cancer Research UK & UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to CRT could reduce the rate of relapse and death among patients with advanced cervical cancer that hasn’t spread to other parts of the body. UCLH consultant clinical oncologist and UCL Cancer Institute scientist Dr Mary McCormack, lead investigator of the trial, said: “A short course of induction chemotherapy prior to standard chemoradiation treatment greatly boosts overall survival and reduces the risk of relapse in patients with locally advanced cervical cancer. “This approach is a straightforward way to make a positive difference, using existing drugs that are cheap and already approved for use in patients. It has already been adopted by some cancer centres and there’s no reason that this shouldn’t be offered to all patients undergoing chemoradiation for this cancer.” Find out more about the trial: https://buff.ly/4eJen66

This #internationalwomensday2024, so proud to see the remarkable impacts in improving women's health made through Roche's long-term partnership to comprehensively enhancing breast cancer care in Vietnam, which is the most common and deadliest form of cancer among women. - Awareness campaigns have successfully reached over 7 million individuals, spreading vital knowledge about breast cancer. - Improved awareness leads to early-stage diagnosis rates for breast cancer soar from less than 30% to an impressive 75%. - Through Roche’s Patient Support Program, provided aid to 431 breast cancer patients, total value of medicinal support reached VNĐ67 billion. Read more: https://lnkd.in/gSVyZj2E https://lnkd.in/gW-zCUkY https://lnkd.in/gwx5bdPy https://lnkd.in/gxMtsuMb #WomensHealth #BreastCancerAwareness #RochePartnership

Quite interesting and innovative as well

Scientific research can do wonders and that is why I love it.

🎉 Former U.S. president, cancer survivor, and immunotherapy advocate, Jimmy Carter, celebrates his 100th birthday today! As a melanoma survivor who publicly announced his diagnosis and immunotherapy treatment in 2015, President Carter has defied all odds to become the first U.S. head of state to live to 100- serving as a testament to the power of immunotherapy. Discover how President Carter ushered immunotherapy into the mainstream, and understand how his courage continues to cause positive ripple effects for cancer patients everywhere, in our new blog post: https://bit.ly/3BpgBsu #CancerResearch #Immunotherapy #JimmyCarter #Melanoma